The company increased its 2018 sales guidance from $140 million – $148 million to $150 million – $158 million. If Tandem posts sales within its newly-revised range, annual revenue would be up 39% – 47% compared to 2017.
The company also noted that its t:slim X2 insulin pump is under review by Canada’s regulatory watchdog and that Tandem hopes to launch the device in Canada in the fourth quarter of this year.
“The sales momentum we are experiencing both domestically and internationally reinforces that we are successfully addressing the needs of people with diabetes worldwide,” president & CEO Kim Blickenstaff said in prepared remarks. “We are increasing our sales guidance as a reflection of this and the tremendous feedback we’ve been receiving on the t:slim X2 insulin pump.”
Last month, Tandem launched its t:slim X2 insulin pump with Basal-IQ technology in the U.S. The pump includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia.